Cholangiocarcinoma Foundation commends FDA approval of new therapy for cholangiocarcinoma patients
CCF provided patient insights into Servier’s development of TIBSOVO® as a treatment for individuals with IDH1-mutated cholangiocarcinoma.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
